Related Experiment Video
Updated: May 16, 2026

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
Published on: July 3, 2020
Mitogen-activated protein kinase 2 regulates physiological and pathological bone turnover
Tobias Braun1, Johannes Lepper, Gisela Ruiz Heiland
1Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nurnberg, Germany.
Mitogen-activated protein kinase 2 (MK2) deficiency impairs osteoclast activity, reducing bone resorption. MK2 knockout mice are protected from age-related bone loss and postmenopausal bone loss, suggesting MK2 inhibitors could treat osteoporosis.
Area of Science:
- Bone Biology and Endocrinology
- Molecular Mechanisms of Bone Homeostasis
- Kinase Signaling in Skeletal Health
Background:
- Bone homeostasis is a dynamic balance between bone resorption by osteoclasts and bone formation by osteoblasts.
- Dysregulation of this balance, particularly increased bone resorption, contributes to conditions like postmenopausal osteoporosis.
- The serine-threonine kinase mitogen-activated protein kinase 2 (MK2) has been implicated in cellular signaling pathways, but its specific role in bone biology remains to be fully elucidated.
Purpose of the Study:
- To investigate the role of mitogen-activated protein kinase 2 (MK2) in regulating bone homeostasis.
- To determine the impact of MK2 deficiency on osteoclast and osteoblast differentiation, function, and gene expression.
- To evaluate the effect of MK2 on age-related bone loss and bone loss induced by ovariectomy.
Main Methods:
- Primary bone cell cultures from MK2(+/+) and MK2(-/-) mice were used to assess osteoclast and osteoblast differentiation and bone resorption.
- Gene expression analysis was performed on osteoclasts.
- In vivo studies involved micro-computed tomography and histomorphometry to analyze bone architecture in MK2(+/+) and MK2(-/-) mice, with and without ovariectomy.
Main Results:
- MK2 deficiency significantly impaired osteoclastogenesis, bone resorption, and osteoclast gene expression.
- Loss of MK2 led to impaired DNA binding of transcription factors c-fos and NFATc1 to key gene promoters involved in osteoclast differentiation.
- MK2(-/-) mice exhibited increased trabecular bone mass, cortical thickness, and reduced bone resorption markers with age, and were protected from ovariectomy-induced bone loss.
- Osteoblastogenesis and bone formation were unaffected, but osteoblast expression and serum levels of osteoprotegerin (OPG) were elevated in MK2(-/-) mice.
Conclusions:
- Loss of MK2 effectively blocks bone resorption by impairing osteoclast differentiation and function.
- MK2 deficiency prevents ovariectomy-induced bone loss, highlighting its critical role in postmenopausal bone loss.
- Small-molecule inhibitors targeting MK2 represent a promising therapeutic strategy for blocking bone resorption and treating postmenopausal bone loss.
Related Concept Videos
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
Bone Remodeling